Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab and Rd with or without Bortezomib in Elderly Transplant-Ineligible Multiple Myeloma
NCT04751877Phase 3Active, not recruiting
- Sponsor
- CHU de Poitiers
- Start
- Jul 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by CHU de Poitiers. Started Jul 2021; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04751877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751877.